In this issue of Nature Metabolism, a gut bacterial glucosidase that degrades the antidiabetic drug acarbose is linked to poor treatment response. Its widespread distribution in the human microbiome could compromise the efficacy of acarbose treatment in many patients.
References
Nauck, M. A., Wefers, J. & Meier, J. J. Lancet Diabetes Endocrinol. 9, 525–544 (2021).
Whang, A., Nagpal, R. & Yadav, H. EBioMedicine 39, 591–602 (2019).
Tian, J. et al. Nat. Metab. https://doi.org/10.1038/s42255-023-00796-w (2023).
Chiasson, J.-L. et al. Lancet 359, 2072–2077 (2002).
Santilli, A. D., Dawson, E. M., Whitehead, K. J. & Whitehead, D. C. ACS Chem. Biol. 13, 1165–1172 (2018).
Maier, L. et al. Nature 555, 623–628 (2018).
Zhang, X. et al. Diabetes Ther. 8, 293–307 (2017).
Balaich, J. et al. Nature 600, 110–115 (2021).
Jang, M.-U. et al. J. Microbiol. 56, 113–118 (2018).
Flint, H. J., Scott, K. P., Duncan, S. H., Louis, P. & Forano, E. Gut Microbes 3, 289–306 (2012).
Tan, K., Tesar, C., Wilton, R., Jedrzejczak, R. P. & Joachimiak, A. Protein Sci. 27, 1498–1508 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Brauny, M.M., Maier, L. Gut bacteria thwart the blood sugar-lowering effect of acarbose. Nat Metab 5, 732–734 (2023). https://doi.org/10.1038/s42255-023-00798-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s42255-023-00798-8
- Springer Nature Limited